Related Experiment Video

Updated: Jan 9, 2026

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy
07:02

Exploring the Arginine Methylome by Nuclear Magnetic Resonance Spectroscopy

Published on: December 16, 2021

1.7K

The PRMT-mediated arginine methylation: From molecular mechanisms to therapeutic targets in cardiovascular diseases

Jia-Qi Tang1, Yang-Kai Wang2, Qi Shen2

  • 1College of Basic Medical Sciences, Naval Medical University (Second Military Medical University), Shanghai, 200433, China; Naval Medical Center, Naval Medical University (Second Military Medical University), Shanghai, 200433, China.

Life Sciences
|December 6, 2025
PubMed

Insights

Protein arginine methyltransferases (PRMTs) are implicated in cardiovascular diseases (CVDs). This review explores their mechanisms and therapeutic potential for conditions like atherosclerosis and heart failure.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiology
  • Translational Medicine

Background:

  • Cardiovascular diseases (CVDs) are a leading global cause of death, with complex pathogenesis hindering effective treatments.
  • Current therapeutic strategies for many CVDs are limited, necessitating novel approaches for early detection and intervention.

Purpose of the Study:

  • To review the mechanistic roles of protein arginine methyltransferases (PRMTs) in the pathogenesis of various cardiovascular diseases.
  • To explore the therapeutic and diagnostic potential of PRMTs in clinical practice for CVD management.

Main Methods:

  • Comprehensive literature review of studies investigating PRMTs in cardiovascular contexts.
  • Analysis of evidence linking PRMTs to molecular mechanisms in atherosclerosis, hypertension, heart failure, ischemic heart disease, and arrhythmogenic cardiomyopathy.

Main Results:

  • Altered levels of PRMTs are observed in patients with CVDs.
  • PRMTs modulate key signaling molecules, including asymmetric dimethylarginine and nitric oxide synthase, impacting disease progression.
  • PRMTs play multifaceted roles in major cardiovascular conditions.

Conclusions:

  • PRMTs are mechanistically involved in the pathogenesis of diverse cardiovascular diseases.
  • Understanding PRMTs' functions provides a foundation for developing novel diagnostic and therapeutic strategies for CVDs.

Keywords:
Asymmetric dimethylarginineCardiovascular diseasesNitric oxide synthaseProtein arginine methyltransferases

More Related Videos

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells08:11

Quantitative Methods to Study Protein Arginine Methyltransferase 1-9 Activity in Cells

Published on: August 7, 2021

4.6K
In vitro Methylation Assay to Study Protein Arginine Methylation10:01

In vitro Methylation Assay to Study Protein Arginine Methylation

Published on: October 5, 2014

15.8K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
426
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
521
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296